Clinical Trial Search

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations — 84; 62; 42; 24 msec — p=0.8842

Primary: Ejection Fraction — 33; 30; 25 % of blood ejected with each beat

Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…

Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL

Primary: Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) — 193; 201; 171; 492 ng/mL

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: Beck Depression Inventory II — 9.3; 9.2; 9.0; 8.6 units on a scale — p=0.90

Primary: Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography — -18.36; -20.81 mL/m^2

Primary: Cohort Retention — 16; 7 participants

Primary: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. — 793; 937…

Primary: Number of Patients With Adverse Events, Serious Adverse Events and Death — 1; 2; 4; 7 Participants

Primary: Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 8.67; 6.86 Patients with event/100 pt-yrs at risk…

Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 5; 5; 7 Participants

Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…

Primary: Treatment Tolerability: Number of Participants Without Discontinuation of Study Intervention (Incl. Max. 1 Day Interruption) and Without Moderate to Severe Symptomatic…

Primary: All Cause Mortality — 163; 118 participants

Primary: Medication Adherence — 91.2; 85.5 percentage of days covered

Primary: Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints — 30; 28; 0; 0 Participants

Primary: Number of Patients Free From Major Adverse Cardiac and Neurological Events (MACNE) at 6 Weeks. — 51 Participants

Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001

Primary: Days Alive and Out of Hospital — 26.9; 25.4 Days Alive and Out of Hospital

Primary: Change From Baseline in Treadmill Exercise Time at Maintenance Phase Week 24 — 424.5; 485.0; 89.5; 37.0 Seconds — p=0.0302

Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters

Primary: Oxygen Uptake (VO2) Peak — 1778.1; 1228.2; 1393.7; 1763.6 ML/KG/Min

Primary: Safety as Measured by the Percentage of Participants Free From System Related Complications Through 6 Months. — 277 Participants

Primary: Bioelectrical Impedance Change — 47.52; 47.1; 41.27; 46.8 Percentage of Extra Cellular Fluid

Primary: Number of Participants With Adverse Events by Severity From Week 0 Through Week 8 (CRV-IR) or Week 14 (SK&F-105517-D) — 0; 1; 2; 5 participants

Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years…

Primary: Patient Quality of Life as Measured on the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score — 54.2; 51.1 score on a scale